Stay updated on SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial

Sign up to get notified when there's something new on the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:42:17.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in a clinical trial study plan involving Sequential Intranodal Immunotherapy combined with Anti-PD1 (Pembrolizumab) in patients with Stage III/IV untreated and relapsed Follicular Lymphoma, aiming to improve rates of immunological and clinical responses.
    Difference
    0.1%
    Check dated 2024-06-06T14:38:15.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.' This change provides a more detailed explanation of the eligibility criteria for participation in the study.
    Difference
    41%
    Check dated 2024-05-22T21:29:43.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:50:57.000Z thumbnail image

Stay in the know with updates to SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page.